Analgesic EfficacyNCT07537036
Analgesic Efficacy of Quadro-Iliac Plane Block Versus Erector Spinae Plane in Total Hip Arthroplasty
A study testing Quadro-iliac plane block and Erector spinae plane block in people with Analgesic Efficacy and Quadro-Iliac Plane Block, run by Tanta University at 1 site in Egypt.
Trial summary
This study aims to compare the Quadro-Iliac Plane Block versus Erector Spinae Plane Block after total hip arthroplasty. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Analgesic Efficacy, Quadro-Iliac Plane Block, Erector Spinae Plane Block
- What is being tested?
- Quadro-iliac plane block and Erector spinae plane block
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 76 participants
- Where
- 1 siteEgypt
- Study dates
- 18 Apr 2026to 30 Nov 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years.
- Both sexes.
- American Society of Anesthesiology (ASA) physical status I-III.
- Undergoing total hip arthroplasty (THA) under spinal anesthesia.
Who cannot join
- History of allergies to local anesthetics.
- Opioid dependency.
- Body mass index (BMI) > 35 kg/m2.
- Cognitive impairment.
- Bleeding or coagulation disorders.
- Psychiatric and neurological disorder.
Show all 9Show fewer
- Local infection at the site of injection.
- Severe heart, lung, liver, and renal dysfunction.
- Emergency surgery.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site, 1 recruiting
- Recruiting
Tanta University
Tanta, El-Gharbia, 31527
Mohammed S Elsharkawy, MD, 00201148207870, mselsharkawy@med.tanta.edu.eg
About this study
Official title: Analgesic Efficacy of Quadro-Iliac Plane Block Versus Erector Spinae Plane in Total Hip Arthroplasty: A Randomized Non-Inferiority Trial
This study aims to compare the Quadro-Iliac Plane Block versus Erector Spinae Plane Block after total hip arthroplasty.
Read the detailed description
Total hip arthroplasty (THA) is frequently utilized in elderly patients to address hip pain and restore joint function. Effective postoperative pain management is critical; however, the use of opioids is associated with a range of adverse effects, including nausea, vomiting, pruritus, constipation, respiratory depression, and the risk of dependence.
Quadro-iliac plane block (QIPB) has been introduced, combining elements of both posterior and anterior QLB approaches.
Erector Spinae Plane Block (ESPB) was initially described as an analgesic approach for managing thoracic neuropathic pain. This innovative fascial block technique enables sensory blockade across multiple abdominal and thoracic wall segments.
- Conditions
- Analgesic Efficacy, Quadro-Iliac Plane Block, Erector Spinae Plane Block, Total Hip Arthroplasty
- Being tested
- Quadro-iliac plane block, Erector spinae plane block
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Quadro-iliac plane blockOther
Patients will receive ipsilateral Quadro-iliac plane block (QIPB) using 20ml of bupivacaine 0.25%.
Erector spinae plane blockOther
Patients will receive ipsilateral erector spinae plane block (ESPB) using 20ml of bupivacaine 0.25%.
| Study group | Role | What they receive |
|---|---|---|
| QIPB group | Experimental | Patients will receive ipsilateral Quadro-iliac plane block (QIPB) using 20ml of bupivacaine 0.25%. Receives: Other: Quadro-iliac plane block |
| ESPB group | Experimental | Patients will receive ipsilateral erector spinae plane block (ESPB) using 20ml of bupivacaine 0.25%. Receives: Other: Erector spinae plane block |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to the first rescue analgesia
Time to the first request for the rescue analgesia will be recorded from the end of surgery to first dose of morphine administrated.
Measured: 24 hours postoperatively
Secondary outcomes (4)
Total morphine consumption
Rescue analgesia of morphine will be given as 3 mg bolus if the numeric rating scale (NRS) > 3 to be repeated after 30 min if pain persists until the NRS < 4.
Measured: 24 hours postoperatively
Degree of pain
Each patient will be instructed about postoperative pain assessment with the numeric rating scale (NRS). NRS (0 represents "no pain" while 10 represents "the worst pain imaginable"). NRS will be assessed at post-anesthesia care unit (PACU), 2, 4, 6, 8, 12, 18, and 24 h postoperatively.
Measured: 24 hours postoperatively
Quality of recovery
The quality of recovery (QoR-15) score, will be assessed 24 hours postoperatively. This tool consists of 15 questions, each scored on a 10-point scale, yielding a maximum of 150. It encompasses five domains; physical comfort (questions 1-4, 13), emotional state (questions 9, 10, 14, 15), psychological support (questions 6, 7), physical independence (questions 5, 8), and pain (questions 11, 12
Measured: 24 hours postoperatively
Incidence of adverse events
Incidence of adverse events such as bradycardia, hypotension, nausea, vomiting, respiratory depression, pruritus, or any other complication will be recorded.
Measured: 24 hours postoperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Apr 2026
- Study start18 Apr 2026
- Primary completion30 Nov 2026 (estimated)
- Study completion30 Nov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Analgesic EfficacyStudies of the same condition, open and under way.
- More trials run by Tanta UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 76 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Tanta University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohammed Said ElSharkawy, Tanta University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07537036
- Sponsor's protocol ID
- 36264PR131011044/3/26
- Status last verified
- Jun 2026
- First submitted
- 11 Apr 2026
- Last updated
- 23 Jun 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Study at a glance
From the registry record, last updated by the sponsor on 23 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Analgesic Efficacy of Quadro-Iliac Plane Block Versus Erector Spinae Plane in Total Hip Arthroplasty: A Randomized Non-Inferiority Trial
- ClinicalTrials.gov ID
- NCT07537036
- Acronym / sponsor ID
- 36264PR131011044/3/26
- Conditions
- Analgesic Efficacy, Quadro-Iliac Plane Block, Erector Spinae Plane Block, Total Hip Arthroplasty
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 76 participants (estimated)
- Lead sponsor
- Tanta UniversityUniversity, hospital or other
- Study start
- 18 Apr 2026 (actual)
- Primary completion
- 30 Nov 2026 (estimated)
- Study completion
- 30 Nov 2026 (estimated)
- First posted
- 17 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to compare the Quadro-Iliac Plane Block versus Erector Spinae Plane Block after total hip arthroplasty.
Detailed description
Total hip arthroplasty (THA) is frequently utilized in elderly patients to address hip pain and restore joint function. Effective postoperative pain management is critical; however, the use of opioids is associated with a range of adverse effects, including nausea, vomiting, pruritus, constipation, respiratory depression, and the risk of dependence.
Quadro-iliac plane block (QIPB) has been introduced, combining elements of both posterior and anterior QLB approaches.
Erector Spinae Plane Block (ESPB) was initially described as an analgesic approach for managing thoracic neuropathic pain. This innovative fascial block technique enables sensory blockade across multiple abdominal and thoracic wall segments.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| QIPB group | Experimental | Other: Quadro-iliac plane blockPatients will receive ipsilateral Quadro-iliac plane block (QIPB) using 20ml of bupivacaine 0.25%. |
| ESPB group | Experimental | Other: Erector spinae plane blockPatients will receive ipsilateral erector spinae plane block (ESPB) using 20ml of bupivacaine 0.25%. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Age ≥ 18 years.
- Both sexes.
- American Society of Anesthesiology (ASA) physical status I-III.
- Undergoing total hip arthroplasty (THA) under spinal anesthesia.
Key exclusion criteria (9 listed)
- History of allergies to local anesthetics.
- Opioid dependency.
- Body mass index (BMI) > 35 kg/m2.
- Cognitive impairment.
- Bleeding or coagulation disorders.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Quadro-iliac plane blockPatients will receive ipsilateral Quadro-iliac plane block (QIPB) using 20ml of bupivacaine 0.25%. | Other | QIPB group |
| Erector spinae plane blockPatients will receive ipsilateral erector spinae plane block (ESPB) using 20ml of bupivacaine 0.25%. | Other | ESPB group |
Primary outcome
Time to the first rescue analgesia
Time frame: 24 hours postoperatively
Time to the first request for the rescue analgesia will be recorded from the end of surgery to first dose of morphine administrated.
4 secondary outcomes
Total morphine consumption
Time frame: 24 hours postoperatively
Degree of pain
Time frame: 24 hours postoperatively
Quality of recovery
Time frame: 24 hours postoperatively
Incidence of adverse events
Time frame: 24 hours postoperatively
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jun 2026.
- Individual participant dataSharing planned: Yes. The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Related trials for Analgesic Efficacy
Not yet recruiting
Human Experimental Models of Pain (HEMP)
Acute Pain
RecruitingPhase 4
PENG With LFCB vs. ESP Blocks for Pediatric Hip Surgery
Hip Disease, Hip Dysplasia
Recruiting
Lumbar Paravertebral Block vs Erector Spinae Plane Block in Elderly Patients Undergoing Lumbar Spine Surgery
Spine Disease
Not yet recruiting
Comparing Long-Acting Local Pain Relief Methods in PLIF Surgery
Posterior Lumbar Interbody Fusion (PLIF), Postoperative Analgesia After Disc Surgery
Recruiting
Marine Lipids Ease Painful TMD
Temporomandibular Disorder (TMD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Quadro-iliac plane block and Erector spinae plane block in people with Analgesic Efficacy and Quadro-Iliac Plane Block, run by Tanta University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 23 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mohammed S Elsharkawy, MD (00201148207870, mselsharkawy@med.tanta.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to the first rescue analgesia (time frame: 24 hours postoperatively). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jun 2026.